Journal of Clinical Oncology, Vol 21, Issue 12
(June), 2003: 2312-2319
© 2003 American Society for Clinical Oncology
Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection
Robert K. Nam,
William W. Zhang,
John Trachtenberg,
Eleftherios Diamandis,
Ants Toi,
Marjan Emami,
Minnie Ho,
Joan Sweet,
Andrew Evans,
Michael A.S. Jewett,
Steven A. Narod
From the Division of Urology, Department of Medical Imaging, Department of Pathology, University Health Network; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; and the Department of Public Health Sciences, University of Toronto, Toronto, Canada.
Address reprint requests to Robert K. Nam, MD, Division of Urology, 2075 Bayview Ave, MG-406, Toronto, Ontario, Canada, M4N 3M5; email: robert.nam{at}utoronto.ca.
Purpose: We examined the relationship between a mutant (T) for wild-type (C) allele substitution of the human kallikrein-2 gene (KLK2), circulating human kallikrein-2 (hK2) levels and prostate cancer risk.
Patients and Methods: We studied 1,287 consecutive men who underwent prostate biopsies because of an abnormal prostate-specific antigen level. Serum and DNA were obtained before biopsy. Cases were patients with cancer, and controls were patients with no cancer. The mutant and wild-type alleles of the KLK2 gene were designated as the T and C alleles, respectively.
Results: Of the 1,287 men, 616 had cancer, and 671 had no cancer. The overall distribution of the CC, CT, and TT KLK2 genotypes was 55.1%, 38.2%, and 6.8%, respectively. The median hK2 levels for men with the CC, CT, and TT genotypes were 0.24, 0.18, and 0.062 ng/mL and correlated with the genotypes, respectively (P = .0001). The adjusted odds ratios for prostate cancer for patients with the TT and CT genotypes compared with patients with the CC genotype, were 2.13 (95% confidence interval [CI], 1.3 to 3.5; P = .004) and 1.51 (95% CI, 1.2 to 2.0; P = .002), respectively. The adjusted odds ratio for prostate cancer for patients in the fourth quartile of hK2 compared with the first quartile was 4.33 (95% CI, 2.9 to 6.4; P = .0001). When combined, the adjusted odds ratio for having prostate cancer was 13.92 (95% CI, 6.6 to 29.2; P = .0001) for patients with high hK2 levels and at least one T allele.
Conclusion: The C/T polymorphism of the KLK2 gene and circulating levels of hK2 are correlated and, in combination, are highly predictive for prostate cancer.
Supported in part by the National Cancer Institute of Canada (Toronto) and the Canadian Urological Association Young Investigators Award.
This article has been cited by other articles:

|
 |

|
 |
 
R. K. Nam, A. Toi, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, S. Appu, D. A. Loblaw, L. Sugar, S. A. Narod, and M. W. Kattan
Assessing Individual Risk for Prostate Cancer
J. Clin. Oncol.,
August 20, 2007;
25(24):
3582 - 3588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Nam, W. W. Zhang, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, J. Sweet, A. Toi, S. Teahan, V. Venkateswaran, L. Sugar, et al.
Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6452 - 6458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod
The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy
Clin. Cancer Res.,
December 1, 2005;
11(23):
8391 - 8397.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res.,
May 1, 2004;
2(5):
257 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al.
Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev.,
December 1, 2003;
12(12):
1429 - 1437.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|